Key points are not available for this paper at this time.
Apalutamide is an oral, nonsteroidal anti-androgen drug that delays disease progression and improves metastases-free and overall survival when added to androgen deprivation therapy in patients with non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer.11,22
Daviduck et al. (Sun,) studied this question.